Benitec Biopharma Limited (ASX:BLT,NASDAQ:BNTC,NASDAQ:BNTCW) has executed a Research Collaboration Agreement with Nant Capital, and has initiated work on two new oncology pipeline programs.
As quoted in the press release:

Under the terms of the executed Research Collaboration Agreement, Benitec has taken control of the
clinical development of BB-401, a recombinant DNA construct that produces an antisense RNA with
specificity against Epidermal Growth Factor Receptor (EGFR). This clinically validated molecular target
is overexpressed in up to 90% of all HNSCC. According to GlobalData (Head and Neck Squamous Cell
Carcinoma – Opportunity Analysis and Forecast to 2024, February 2016), approximately 64,000 new
patients will be diagnosed annually in the US with HNSCC and 50% of the patients are expected to
develop recurrent or metastatic disease, with approximately 13,000 annual deaths expected in the US
from HNSCC.

Click here for the full press release.